# Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

> **NCT05016544** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 48 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** inetetamab
- **DRUG:** Pytotinib

## Key facts

- **NCT ID:** NCT05016544
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-28
- **Primary completion:** 2023-08-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016544, "Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05016544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*